Feedback control of excitability and high K + induced epileptiform bursts in male rat hippocampal slices with a photocaged adenosine A 1 receptor agonist
British Journal of Pharmacology · 2026
DOI: 10.1111/bph.70349 ↗At a glance
Journal article in British Journal of Pharmacology, 2026. Written by Erine Craey and 8 co-authors. Institution: 4Brain, Department of Head and Skin, Ghent University, Ghent, Belgium. Major MEDLINE topics: Hippocampus, Adenosine A1 Receptor Agonists, Adenosine, Receptor, Adenosine A1. 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: Research Foundation Flanders, Ghent University Special Research Fund, Queen Elisabeth Medical Foundation.
Abstract (original language)
Background and Purpose Adenosine is a potent regulator of neurotransmission and neuronal excitability, through activation of G i coupled adenosine A 1 receptors (A 1 Rs). Adenosine has gained interest as an anticonvulsant because of its endogenous involvement in ending seizure activity, but peripheral side effects require local application. We recently developed a coumarin‐caged derivative of the A 1 R agonist N 6 ‐cyclopentyl‐adenosine (CPA), which can be used to release CPA with millisecond light flashes. In the hippocampal neuronal network, CPA reduces excitability. Experimental Approach A closed‐loop feedback system recorded field potentials evoked in male rat hippocampal slices on a 64‐channel multielectrode array; it extracted relevant parameters and used an algorithm to photorelease CPA to control and limit excitability. Raising extracellular K + concentration to 8.5 mM, a common ex vivo epilepsy model induced regularly occurring epileptiform bursts, when it was still possible to monitor field potentials. Key Results The reduction of excitability in response to CPA photorelease was quantified, and the feedback system was analysed and fine‐tuned. Eventually, the feedback system was able to automatically evolve to a setpoint that almost completely suppressed the epileptiform bursts, whilst maintaining about ~50% of baseline neurotransmission. This not only offers a new strategy to fight difficult to treat epilepsies but also creates a research platform for the study of neuronal networks in a well‐defined state of excitability. Conclusions and Implications Combining photopharmacological adenosinergic modulation with real‐time field potential monitoring provides a first step towards closed‐loop precision treatment for diseases related to neuronal hyperexcitability, such as epilepsy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- 4Brain, Department of Head and Skin, Ghent University, Ghent, Belgium.
- Laboratory for Medicinal Chemistry, Department of Pharmaceutics, Ghent University, Ghent, Belgium.
ORCID profiles: Robrecht Raedt
Funding
- Research Foundation Flanders
- Ghent University Special Research Fund
- Queen Elisabeth Medical Foundation
- Margaret Olivia Knip Foundation
- Fonds Wetenschappelijk Onderzoek
Cite
APA
Craey, E., Vergaelen, M., Van Calenbergh, S., Spanoghe, J., Carrette, E., Vonck, K., Boon, P., Wadman, W. J., & Raedt, R. (2026). Feedback control of excitability and high K + induced epileptiform bursts in male rat hippocampal slices with a photocaged adenosine A 1 receptor agonist. British Journal of Pharmacology. https://doi.org/10.1111/bph.70349
Vancouver
Craey E, Vergaelen M, Van Calenbergh S, Spanoghe J, Carrette E, Vonck K, et al. Feedback control of excitability and high K + induced epileptiform bursts in male rat hippocampal slices with a photocaged adenosine A 1 receptor agonist. British Journal of Pharmacology. 2026. doi:10.1111/bph.70349
BibTeX
@article{Craey2026,
author = {Craey, Erine and Vergaelen, Marijke and Van Calenbergh, Serge and Spanoghe, Jeroen and Carrette, Evelien and Vonck, Kristl and Boon, Paul and Wadman, Wytse J and Raedt, Robrecht},
title = {Feedback control of excitability and high K + induced epileptiform bursts in male rat hippocampal slices with a photocaged adenosine A 1 receptor agonist},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70349}
}
EUVIMED